GlassScriptPhysician profile
Steven Lommatzsch
NPI 1750309571
$6,256.70
in general payments reported to CMS, 2019-2025
15 companies · $4,650 in 2025
The $4,650 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $215 · 2021: $438 · 2022: $457 · 2023: $139 · 2025: $4,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,500 · Food and Beverage: $723 · Travel and Lodging: $548 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,500.00 |
| Food and Beverage | $723.36 |
| Travel and Lodging | $547.95 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $4,072.99 | 2025 | |
| Insmed, INC. | $524.84 | 2019-2025 | Arikayce |
| Glaxosmithkline, LLC. | $437.49 | 2019-2022 | |
| Abbvie INC. | $294.78 | 2022-2025 | |
| Pharming Healthcare, INC. | $246.57 | 2023-2025 | Joenja |
| Genentech USA, INC. | $196.26 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $141.90 | 2020-2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.16 | 2025 | Ofev |
| Allergan, INC. | $84.69 | 2019-2020 | |
| Pulmonx Corporation | $77.72 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Genzyme Corporation | $28.25 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.70 | 2020 | |
| Gilead Sciences, INC. | $13.68 | 2022 | |
| Olympus America INC. | $13.67 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lommatzsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.